null René St-Arnaud, PhD
gene expression in osteoblasts • vitamin D • animal models of bone disease • bone fracture repair
My research program aims to identify, characterize and validate targets for pharmacological intervention and the development of rational, effective novel therapeutics for bone regenerative medicine. My team uses an integrated approach with biochemistry, molecular/cell biology, mouse molecular genetics and preclinical science to cover the full bench-to-bedside spectrum: target identification and characterization, high-throughput screening of small molecules for drug development, and validation of lead compounds. With surgeon colleagues, we are preparing a clinical trial to test the efficacy of 24,25-dihydroxyvitamin D to improve osteotomy healing.
Click on to see my current publications list
Martineau, C., R.P. Naja, A. Husseini, B. Hamade, M. Kaufmann, O. Akhouayri, A. Arabian, G. Jones, and R. St-Arnaud. 2018. Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2. J. Clin. Invest. 128: 3546-3557. PMID: 30010626.
Addison, W.N., M. Pellicelli, and R. St-Arnaud. 2019. Dephosphorylation of the transcriptional cofactor NACA by the PP1A phosphatase enhances cJUN transcriptional activity and osteoblast differentiation. J. Biol. Chem. 294: 8184-8196. PMID: 30948508.
Hariri, H., M. Pellicelli, and R. St-Arnaud. 2020. Nfil3, a target of the NACA transcriptional coregulator, affects osteoblast and osteocyte gene expression differentially. Bone 141: 115624. PMID: 32877713.
St-Arnaud, R., M. Pellicelli, M. Ismail, A. Arabian, T. Jafarov, and C.J. Zhou. 2022. NACA and LRP6 are part of a common genetic pathway necessary for full anabolic response to intermittent PTH. Int. J. Mol. Sci. 23: 940. PMID: 35055125.
St-Arnaud, R., A. Arabian, D. Kavame, M. Kaufmann, and G. Jones. 2022. Vitamin D and diseases of mineral homeostasis: a Cyp24a1 R396W humanized preclinical model of Infantile Hypercalcemia type 1. Nutrients 14: 3221. PMID: 35956396.